In this free webinar, hear from CNS thought-leaders on the transformative power of objective measures of brain function in neuropsychiatry clinical trials. Attendees will gain insight into the power of EEG data synchronized with behavioural assessment data for measuring drug target engagement and cognition in a clinical trial for major depressive disorder.
TORONTO, Oct. 6, 2025 /PRNewswire/ — The need for neuropsychiatry clinical trials to evolve is crucial. Traditional measures lack sensitivity, elevating the need for novel, objective measures, which can measure drug target engagement in phase 1 trials, and combat placebo effects with
low-touch home-based sampling. This webinar highlights critical advances in portable neurotechnology which enable the collection of real-world objective data, and features key findings from a Phase Ib study presented at the 38th European College of Neuropsychiatry (ECNP) annual meeting.
DLX-001 (zalsupindole) is a clinical-stage, novel neuroplastogen, in development for the treatment of major depressive disorder and illustrates the evolving landscape. The broader therapeutic approach centers on neuroplasticity-promoting compounds intended to address neuropsychiatric and neurological conditions in which there exists high unmet need.
The featured speakers in this webinar will showcase data demonstrating the power of multimodal measurements for measuring drug target engagement in a clinical trial for major depressive disorder.
Register today to learn how sensitive, objective, real-world data collection can accelerate the evolution of neuropsychiatric clinical trials and the clinical development of effective CNS therapies to improve the lives of millions of people living with neuropsychiatric conditions.
Join Dr. Aaron Koenig, MD, CMO, Delix Therapeutics; and Dr. Brian Murphy, PhD, Co-Founder and CSO, Cumulus Neuroscience, for the live webinar on Tuesday, October 21, 2025, at 1pm EDT (10am PDT).
For more information or to register for this event, visit Neuropsychiatry Clinical Trials: Evolving with Portable EEG and Digital Endpoints.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks, visit www.xtalks.com
For information about hosting a webinar, visit www.xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com
SOURCE Xtalks
Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…
Telehealth Platform Facilitates Compounded Semaglutide and Tirzepatide Access Through Licensed Provider Evaluation as FDA Shortage…
Analysis examines best peptides for boosting growth hormone as ReadyRx lists prescription sermorelin in injectable…
Discover the best fat burner for men in 2025. Explore Wolfson Brand’s effective fat-burning supplements…
Industry Analysis Examines How Cost, Safety, and Access Considerations Shape Semaglutide Choices as MEDVi Lists…
Deploying “Proof of Human” Infrastructure throughout Japan, a Technology Envisioned by Sam Altman and Alex…